Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AssigneeNkarta, Inc.
InventorsDaofeng Liu, Guangnan Li, James B. Trager
Life of this patent
Estimating the term…
Abstract
Several embodiments disclosed herein relate to methods and processes for the co-expansion of multiple types of immune cells, in order to generate a mixed cell population. Some embodiments relate to the use of various stimuli specific to the various subpopulations to achieve expansion of those subpopulations at a particular time in a culturing process in order to generate an expanded population of immune cells having a desired ratio of the various subpopulations. In several embodiments, such mixed cell populations exhibit desirable characteristics, such as cytotoxic effects against tumor cells that enhance the efficacy of cancer immunotherapy.
Claims22
A method for the generation of a mixed population of engineered immune cells comprising at least two subpopulations of engineered immune cells, the method comprising:
- (a) isolating a population of mononuclear cells from a blood sample, wherein the isolated population of mononuclear cells comprises at least a first and a second subpopulation of immune cells;
- (b) isolating the first subpopulation of immune cells from the isolated mononuclear cells, wherein the first subpopulation of immune cells comprises natural killer (NK) cells;
- (c) culturing the first subpopulation of isolated immune cells with a population of feeder cells in a culture vessel, wherein the feeder cells express at least one molecule selected from 4-1BB ligand (4-1BBL), interleukin 15 (IL15), and combinations thereof, thereby generating an expanded population of NK cells;
- (d) isolating the second subpopulation of immune cells from the isolated mononuclear cells, wherein the second subpopulation of immune cells comprises T cells;
- (e) culturing the second subpopulation of immune cells in a culture vessel with at least one molecule comprising one or more of an antibody directed against CD3 or against CD28, thereby generating an expanded population of T cells;
- (f) transducing the expanded NK cell population with a nucleic acid encoding an engineered receptor that binds a target expressed by a cancer cell, thereby generating engineered NK cells;
- (g) transducing the expanded T cell population with a nucleic acid encoding an engineered receptor that binds a target expressed by a cancer cell, thereby generating engineered T cells;
- and
- (h) combining a portion of the engineered NK cells with a portion of the engineered T cells, wherein the ratio of engineered NK cells to engineered T cells is between about 5:1 and about 20:1.
A method for the generation of a mixed population of engineered immune cells comprising at least two subpopulations of engineered immune cells, the method comprising:
- (a) isolating a population of mononuclear cells from a blood sample, wherein the isolated population of mononuclear cells comprises at least a first and a second subpopulation of immune cells;
- (b) isolating the first subpopulation of immune cells from the isolated mononuclear cells, wherein the first subpopulation of immune cells comprises natural killer (NK) cells;
- (c) culturing the first subpopulation of isolated immune cells with a population of feeder cells in a culture vessel, wherein the feeder cells express 4-1BB ligand (4-1BBL) and interleukin 15 (IL15), thereby generating an expanded population of NK cells;
- (d) isolating the second subpopulation of immune cells from the isolated mononuclear cells, wherein the second subpopulation of immune cells comprises T cells;
- (e) culturing the second subpopulation of immune cells in a culture vessel with an anti-CD3 antibody and an anti-CD28 antibody, thereby generating an expanded population of T cells;
- (f) transducing the expanded NK cell population with a nucleic acid encoding a chimeric antigen receptor (CAR) that binds to CD19, thereby generating engineered NK cells;
- (g) transducing the expanded T cell population with a nucleic acid encoding a CAR that binds to CD19, thereby generating engineered T cells;
- and
- (h) combining a portion of the engineered NK cells with a portion of the engineered cells, wherein the ratio of engineered NK cells to engineered T cells is betweenat least about 5:1 and about 20:1.
Dependencies are inferred from the claim text.